Bicombinatorial discovery of small molecule tags

Information

  • Research Project
  • 6488312
  • ApplicationId
    6488312
  • Core Project Number
    F32GM065048
  • Full Project Number
    1F32GM065048-01A1
  • Serial Number
    65048
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/2002 - 22 years ago
  • Project End Date
    -
  • Program Officer Name
    IKEDA, RICHARD A.
  • Budget Start Date
    5/1/2002 - 22 years ago
  • Budget End Date
    4/30/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    4/25/2002 - 22 years ago

Bicombinatorial discovery of small molecule tags

DESCRIPTION: (provided by applicant) Development of a novel bicombinatorial screen will allow isolation of small molecule compounds (about 180 daltons) that interact specifically with individual intracellular proteins. By screening a combinatorial library of compounds against a combinatorial library of protein targets the chance of discovering specific compound-protein pairs will be maximized. Typically a compound must interact with a protein very strongly in order to be specific. This screen will take advantage of tethering technology, which uses a secondary disulfide tether between the small molecule and a cysteine on the protein to stabilize interacting complexes. This allows specific binding even when the interaction energy is low, so the likelihood of finding interacting molecules is dramatically increased, and the compound library can be relatively small. The compounds can be rapidly converted to fluorescent tags to study protein localization, or to affinity compounds to isolate the protein they recognize alone and in complexes. These compounds will also be useful as novel lead compounds for drug discovery. In contrast to conventional drug screens which focus on a single protein target, the bicombinatorial screen should suggest both which chemical moities are the most effective in binding proteins, and which chemical constituents confer anti-specificity. It may also be able to suggest some unexploited families of proteins that would also be suitable as drug targets.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    F32
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    37220
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:37220\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SUNESIS PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SOUTH SAN FRANCISCO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94080
  • Organization District
    UNITED STATES